Skip to content

Clinical trials

Glioblastoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glioblastoma Clear all

2,065 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200028
200131
200235
200322
200434
200552
200656
200762
200865
200967
201076
201171
201257
201373
201476
201569
201689
201785
2018109
201979
202098
202188
2022107
2023104
2024105
2025105
2026112

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed937
Recruiting304
Terminated252
Unknown status194
Active, not recruiting162
Not yet recruiting90
Withdrawn87
Suspended16
No longer available10
Enrolling by invitation7
Available6

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)120
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins55
Duke University52
M.D. Anderson Cancer Center43
Jonsson Comprehensive Cancer Center27
City of Hope Medical Center23
Case Comprehensive Cancer Center22
Mayo Clinic22
Memorial Sloan Kettering Cancer Center21
Novartis Pharmaceuticals20

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glioblastoma2,065
Brain Neoplasms601
Glioma596
Gliosarcoma476
Astrocytoma450
Oligodendroglioma263
Central Nervous System Neoplasms253
Neoplasms117
Ependymoma108
Recurrence71

Trials

Showing 51 to 75 of 2,065. Each trial links to its page on Pharma Observatory.

1,965 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.